Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP9521 phase I/II study in metastatic castration-resistant prostate cancer
NL-OMON38103Phase 2Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ASP9521 in prostate cancer (PCa) (3 arms), sponsored by Astellas Pharma. Primary endpoints: PSA response rate, Safety and tolerability and 1 more. Planned start Jul 2011; status: withdrawn.
02
Drugs
ASP9521
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON38103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38103.